for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zogenix, Inc.

ZGNX.O

Latest Trade

21.44USD

Change

0.12(+0.56%)

Volume

198,380

Today's Range

21.04

 - 

21.60

52 Week Range

16.65

 - 

57.22

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
21.32
Open
21.19
Volume
198,380
3M AVG Volume
25.93
Today's High
21.60
Today's Low
21.04
52 Week High
57.22
52 Week Low
16.65
Shares Out (MIL)
55.45
Market Cap (MIL)
1,131.97
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Zogenix Inc Earnings Release

Latest Developments

More

Zogenix Announces Proposed Convertible Senior Notes Offering

Zogenix Announces Positive Top-Line Results From Its Third Pivotal Phase 3 Clinical TrialOf Fintepla In Dravet Syndrome

Zogenix Provides Corporate Update And Reports Second Quarter 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zogenix, Inc.

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

Industry

Biotechnology & Drugs

Contact Info

5959 Horton St Ste 500

EMERYVILLE, CA

94608-2120

United States

+1.510.5508300

http://www.zogenix.com/

Executive Leadership

Cam L. Garner

Independent Chairman of the Board

Stephen J. Farr

President, Chief Executive Officer, Director

Michael P. Smith

Chief Financial Officer, Executive Vice President, Treasurer

Shawnte M. Mitchell

Executive Vice President, General Counsel, Secretary

Gail M. Farfel

Executive Vice President, Chief Development Officer

Key Stats

1.85 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-4.650

2018

-3.270

2019

-9.740

2020(E)

-3.574
Price To Earnings (TTM)
--
Price To Sales (TTM)
232.92
Price To Book (MRQ)
2.79
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-85.09
Return on Equity (TTM)
-73.41

Latest News

Latest News

FDA approves Zogenix's drug for rare childhood epilepsy

The U.S Food and Drug Administration on Thursday approved Zogenix Inc's drug to treat seizures associated with a rare form of childhood epilepsy known as Dravet syndrome.

BRIEF-FDA Approves New Therapy For Dravet Syndrome

* U.S. FDA - APPROVED FINTEPLA, A SCHEDULE IV CONTROLLED SUBSTANCE, FOR TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME

FDA approves Zogenix's drug for rare childhood epilepsy

The U.S Food and Drug Administration on Thursday approved Zogenix Inc's drug to treat seizures associated with a rare form of childhood epilepsy known as Dravet syndrome. (https://reut.rs/3g2naBs)

BRIEF-Zogenix Prices Public Offering Of Common Stock

* PRICED AN UNDERWRITTEN PUBLIC OFFERING OF 8,520,000 SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $23.50 PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Zogenix Announces Proposed Public Offering Of Common Stock

* ZOGENIX - TO USE NET PROCEEDS FROM OFFERING TO SUPPORT ACTIVITIES RELATED TO POTENTIAL COMMERCIALIZATION OF FINTEPLA, AMONG OTHER THINGS Source text for Eikon: Further company coverage:

BRIEF-Zogenix Announces FDA Extension Of Review Period For Fintepla In Dravet Syndrome

* ZOGENIX ANNOUNCES FDA EXTENSION OF REVIEW PERIOD FOR FINTEPLA® IN DRAVET SYNDROME

BRIEF-Zogenix Inc Disclosed Estimated, Unaudited Cash, Cash Equivalents & Marketable Securities As Of Dec 31, Were $251.2 Mln

* ZOGENIX INC - DISCLOSED ESTIMATED, UNAUDITED CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES AS OF DEC 31, 2019 WERE $251.2 MILLION Source: (http://bit.ly/2tU21GX) Further company coverage:

BRIEF-Zogenix Announces Positive Top-Line Results From Global Pivotal Phase 3 Trial Of Fintepla

* ZOGENIX ANNOUNCES POSITIVE TOP-LINE RESULTS FROM GLOBAL PIVOTAL PHASE 3 TRIAL OF FINTEPLA® FOR THE TREATMENT OF LENNOX-GASTAUT SYNDROME

Zogenix's seizure drug filing fails to pass U.S. FDA scrutiny

The U.S. Food and Drug Administration on Monday refused to fully review the marketing application for Zogenix Inc's treatment for seizures associated with Dravet syndrome, a rare form of childhood epilepsy.

U.S. FDA refuses to review Zogenix's seizure treatment

The U.S. Food and Drug Administration on Monday refused to review the marketing application for Zogenix Inc's treatment for seizures associated with Dravet syndrome, a rare form of childhood epilepsy, the company said. (Reporting by Manas Mishra in Bengaluru; Editing by...

Zogenix's seizure drug clears late-stage trial, shares soar

Zogenix Inc <ZGNX.O> said on Thursday its drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer's shares up as much as 26 percent.

Zogenix's treatment for rare epilepsy meets advanced study goal

Zogenix Inc said on Thursday its drug to treat Dravet syndrome, a rare form of epilepsy, met the main goal of a late-stage trial.

BRIEF-Zogenix Q1 Loss Per Share $0.87

* ZOGENIX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER FINANCIAL RESULTS

BRIEF-Zogenix Inc Q4 Loss Per Share $1.17

* ZOGENIX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Zogenix Completes Enrollment In Second ZX008 Phase 3 Clinical Trial In Dravet Syndrome

* ZOGENIX COMPLETES ENROLLMENT IN SECOND ZX008 PHASE 3 CLINICAL TRIAL IN DRAVET SYNDROME

BRIEF-Zogenix Says May Issue And Sell Shares Of Common Stock Having An Aggregate Offering Price Of Up To $75.0 Mln

* ZOGENIX INC - MAY ISSUE AND SELL SHARES OF COMMON STOCK HAVING AN AGGREGATE OFFERING PRICE OF UP TO $75.0 MILLION Source text: (http://bit.ly/2kHM2Eb) Further company coverage:

BRIEF-Zogenix Announces New Data From Pivotal Phase 3 Clinical Trial Of ZX008

* ZOGENIX ANNOUNCES NEW POSITIVE EFFICACY AND SAFETY DATA FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME

BRIEF-Zogenix posts Q3 loss of $1.68 per share

* Zogenix provides corporate update and reports third quarter 2017 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up